Fusen Pharm (01652.HK): Four Products Proposed to Be Selected in the 12th National Centralized Drug Procurement
NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) issued a voluntary announcement on 3 August 2026. In the tender of China’s 12th National Centralized Drug Procurement held on 31 July 2026, four products of the Company are proposed to be selected: Nicardipine Injection (2ml:2mg, 5ml:5mg), Azilsartan Potassium Tablets (40mg, 80mg), Potassium Hydrogen Phosphate Compound Injection (5ml: 1.12g Potassium Dihydrogen Phosphate and 1.18g Dipotassium Hydrogen Phosphate (calculated as K₂HPO₄)), and Dydrogesterone Tablets (10mg).
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- FUSEN PHARM(01652.HK): Peramivir Injection Granted Marketing Approval; Domestic Market Size Exceeded RMB800 Million in 2025
- FUSEN PHARM (01652.HK): Piracetam Injection Approved for Marketing, Market Size Exceeds RMB250 Million in 2025
- Global X Gold Covered Call Active Etf(03533.HK) Slips 0.42% Intraday to HK$70.74
- BANKCOMM (03328.HK): Completes RMB40 Billion Tier 2 Capital Bond Issuance with Coupon Rate of 1.89%
- Harvest Green Power ETF (159625) rises 1.22%, with a scale increase of 195 million yuan over the past week
